Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism.
We investigated olfactory function and its relation to cardiac 123I-metaiodobenzylguanidine (MIBG) uptake in 15 patients with drug induced parkinsonism (DIP). The mean Cross Cultural Smell Identification (CCSI) score was significantly greater in patients with DIP than in those with Parkinson's disease (PD: 6.9 (1.6) vs 4.4 (2.2); p<0.001); however, the mean CCSI score in patients with DIP was not significantly different from controls. One patient with DIP, whose CCSI score was significantly reduced, also exhibited decreased cardiac MIBG uptake. DIP patients with CCSI scores within the normal range had normal cardiac MIBG uptake. Our study suggests that an olfactory function test may be a useful tool for detecting DIP unrelated to PD and for identifying patients with DIP who have subclinical PD.
Lee
Phil Hyu
PH
Department of Neurology, Ajou University School of Medicine, Woncheon-dong San 5, Paldal-gu, Suwon, Gyeonggi-do, 442-749, Korea. phisland@chol.com
Yeo
Seung Hyeon
SH
Yong
Seok Woo
SW
Kim
Yun Joong
YJ
D019797:3-Iodobenzylguanidine; D000368:Aged; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006321:Heart / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008482:Mediastinum / Q000000981:diagnostic imaging; D008875:Middle Aged; D000857:Olfaction Disorders / Q000139:chemically induced* / Q000000981:diagnostic imaging; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000000981:diagnostic imaging; D012903:Smell / Q000187:drug effects*; D015899:Tomography, Emission-Computed, Single-Photon
D019797:3-Iodobenzylguanidine